Pyxis Oncology announced today that it will present new preclinical data on its mouse analogue of MICVO (maMICVO) at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California. The presentation will take place during the conference’s poster session, which runs from April 17 to April 22, 2026.
The preclinical study showed that maMICVO monotherapy produced dose‑dependent inhibition of tumor growth in a syngeneic head‑and‑neck squamous cell carcinoma (HNSCC) model. In combination with anti‑mouse PD‑1, maMICVO demonstrated synergistic anti‑tumor activity, achieving greater tumor control than either agent alone in an immunotherapy‑refractory setting. These findings reinforce the company’s strategy of combining MICVO with pembrolizumab (KEYTRUDA®) in its Phase 1/2 clinical trial for recurrent/metastatic HNSCC.
The data are intended to support MICVO’s ongoing clinical development, with the company expecting to report updated Phase 1 monotherapy results in mid‑2026 and Phase 1/2 combination results in the second half of 2026. The presentation underscores Pyxis’s commitment to advancing its first‑in‑concept extracellular‑matrix‑targeting ADC platform and may influence future partnership or funding decisions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.